CD34 and diabetes mellitus: The flow cytometry assay shows that the number of circulating EPCs (CD34+/VEGFR2+) significantly decreases in the diabetes group, while PCB2 treatment significantly preserves the circulating EPC number compared to diabetic mice (Figure 7B).